AVTX 股價走勢圖
AVTX 股票價格預測
Avalo Therapeutics Inc
$20.25
-6.11%
$-1.32
收盤價：May 11, 16:00:00 GMT-4
$20.05
-0.98%
$-0.19
盤前：May 12, 06:49:44 GMT-4
返回
Avalo Therapeutics Inc (AVTX) 股票價格預測
關鍵數據
前收市價
$21.57
開盤價
$21.86
當日範圍
$19.8 - $22.02
52週區間
$3.39 - $20.72
交易量
2.8M
平均成交量
630.2K
股息收益率
--
每股盈餘 (TTM)
-6.39
市值
$535.5M
什麼是 AVTX？
Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. The company is headquartered in Wayne, Pennsylvania and currently employs 33 full-time employees. The company went IPO on 2015-11-13. The firm's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).
